1. Home
  2. BEAM vs UAA Comparison

BEAM vs UAA Comparison

Compare BEAM & UAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • UAA
  • Stock Information
  • Founded
  • BEAM 2017
  • UAA 1996
  • Country
  • BEAM United States
  • UAA United States
  • Employees
  • BEAM N/A
  • UAA N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • UAA Apparel
  • Sector
  • BEAM Health Care
  • UAA Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • UAA Nasdaq
  • Market Cap
  • BEAM 2.3B
  • UAA 2.2B
  • IPO Year
  • BEAM 2020
  • UAA N/A
  • Fundamental
  • Price
  • BEAM $25.14
  • UAA $4.67
  • Analyst Decision
  • BEAM Strong Buy
  • UAA Hold
  • Analyst Count
  • BEAM 12
  • UAA 19
  • Target Price
  • BEAM $48.09
  • UAA $6.53
  • AVG Volume (30 Days)
  • BEAM 2.3M
  • UAA 10.8M
  • Earning Date
  • BEAM 11-04-2025
  • UAA 11-06-2025
  • Dividend Yield
  • BEAM N/A
  • UAA N/A
  • EPS Growth
  • BEAM N/A
  • UAA N/A
  • EPS
  • BEAM N/A
  • UAA N/A
  • Revenue
  • BEAM $55,701,000.00
  • UAA $5,049,070,000.00
  • Revenue This Year
  • BEAM N/A
  • UAA N/A
  • Revenue Next Year
  • BEAM $19.01
  • UAA $2.26
  • P/E Ratio
  • BEAM N/A
  • UAA N/A
  • Revenue Growth
  • BEAM N/A
  • UAA N/A
  • 52 Week Low
  • BEAM $13.53
  • UAA $4.13
  • 52 Week High
  • BEAM $35.25
  • UAA $10.53
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 58.18
  • UAA 53.77
  • Support Level
  • BEAM $20.23
  • UAA $4.13
  • Resistance Level
  • BEAM $22.72
  • UAA $4.35
  • Average True Range (ATR)
  • BEAM 1.68
  • UAA 0.19
  • MACD
  • BEAM 0.36
  • UAA 0.02
  • Stochastic Oscillator
  • BEAM 97.41
  • UAA 73.29

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About UAA Under Armour Inc.

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

Share on Social Networks: